Alkermes Balance Sheet Health
Financial Health criteria checks 6/6
Alkermes has a total shareholder equity of $1.3B and total debt of $288.8M, which brings its debt-to-equity ratio to 22.4%. Its total assets and total liabilities are $2.2B and $863.2M respectively. Alkermes's EBIT is $318.6M making its interest coverage ratio -18.9. It has cash and short-term investments of $908.9M.
Key information
22.4%
Debt to equity ratio
US$288.82m
Debt
| Interest coverage ratio | -18.9x |
| Cash | US$908.86m |
| Equity | US$1.29b |
| Total liabilities | US$863.19m |
| Total assets | US$2.16b |
Recent financial health updates
Is Alkermes (NASDAQ:ALKS) A Risky Investment?
Sep 17
Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Apr 08Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?
Nov 01Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?
Jul 15Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Mar 20Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?
Aug 29Recent updates
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Nov 24Alkermes plc's (NASDAQ:ALKS) Low P/E No Reason For Excitement
Oct 14Is Alkermes (NASDAQ:ALKS) A Risky Investment?
Sep 17Alkermes: Fairly Valued After Post-Earnings Bump
Jul 28Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?
Jul 26Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry
Jul 04The Bottom Fishing Club: Alkermes Has Great Value And Safety
May 17Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals
May 08Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Apr 09Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Apr 08Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet
Jan 26Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?
Nov 01Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point
Nov 01Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?
Jul 15There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding
Jun 07Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?
Apr 10Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?
Mar 20Alkermes upgraded to neutral at BofA on improved risk/reward outlook
Oct 14Alkermes holder Sarissa Capital says it may look to increase its stake
Oct 07Alkermes: Nothing Stands Out As Interesting
Sep 26Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?
Aug 29Alkermes initiated at neutral at Piper Sandler as company in transition
Aug 16Alkermes Q2 2022 Earnings Preview
Jul 26Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 44% Undervaluation?
Jun 27Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?
May 16Alkermes: Turning The Tides Towards Profitability
Apr 16Financial Position Analysis
Short Term Liabilities: ALKS's short term assets ($1.6B) exceed its short term liabilities ($453.7M).
Long Term Liabilities: ALKS's short term assets ($1.6B) exceed its long term liabilities ($409.5M).
Debt to Equity History and Analysis
Debt Level: ALKS has more cash than its total debt.
Reducing Debt: ALKS's debt to equity ratio has reduced from 26% to 22.4% over the past 5 years.
Debt Coverage: ALKS's debt is well covered by operating cash flow (123.2%).
Interest Coverage: ALKS earns more interest than it pays, so coverage of interest payments is not a concern.